<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924322</url>
  </required_header>
  <id_info>
    <org_study_id>2000030683</org_study_id>
    <nct_id>NCT04924322</nct_id>
  </id_info>
  <brief_title>Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies</brief_title>
  <acronym>CRETE</acronym>
  <official_title>Age-dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-associated Thrombosis in Critically Ill Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Healthcare of Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BJC HealthCare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's of Alabama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Golisano Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Fareri Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the CRETE Studies is to investigate the newly identified age-dependent&#xD;
      heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous&#xD;
      catheter-associated deep venous thrombosis in critically ill children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric venous thromboembolism (VTE), which is predominantly deep venous thrombosis (DVT),&#xD;
      is a top contributor to harm in hospitalized children. Its incidence increased by &gt;300% in&#xD;
      the past 2 decades. Critical illness and central venous catheter (CVC) are the most important&#xD;
      risk factors for VTE in children. Among critically ill children, the risk of CVC-associated&#xD;
      DVT (CADVT) is as high as 54% with 72% of cases in infants &lt;1-year old. Pharmacologic&#xD;
      prophylaxis is the most effective strategy against VTE in adults. However, due to paucity of&#xD;
      age-appropriate evidence on its efficacy against CADVT, pharmacologic prophylaxis is uncommon&#xD;
      in children. Extrapolation of evidence from adults is not appropriate because the hemostatic&#xD;
      system changes significantly with age. The investigators recently completed a Bayesian phase&#xD;
      2b randomized clinical trial. In this trial, the investigators randomized critically ill&#xD;
      children to early administration of prophylactic dose of enoxaparin, the most commonly used&#xD;
      anticoagulant for prophylaxis, or usual care. Prophylaxis with enoxaparin appeared to reduce&#xD;
      the risk of CADVT by half. In post hoc analyses, reduction was limited to older children 1-17&#xD;
      years old. The goal of the CRETE Studies is to investigate this newly identified&#xD;
      age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of CADVT in&#xD;
      critically ill children. To achieve this goal, the investigators aim (1) to confirm the&#xD;
      efficacy and safety of early administration of prophylactic dose of enoxaparin in reducing&#xD;
      the risk of CADVT in critically ill older children; (2) to determine the efficacy and safety&#xD;
      of early administration of therapeutic dose of enoxaparin in reducing the risk of CADVT in&#xD;
      critically ill infants; and, (3) to probe the mechanisms that underly the age-dependent&#xD;
      heterogeneity in the efficacy of enoxaparin in reducing the risk of CADVT in critically ill&#xD;
      children. The investigators will conduct 2 multicenter Bayesian explanatory randomized&#xD;
      clinical trials in parallel to address Specific Aims 1 and 2. Depending on age, subjects will&#xD;
      be randomized to different doses of enoxaparin vs usual care. Subjects will be systematically&#xD;
      assessed for the development of CADVT using ultrasonography and clinically for bleeding.&#xD;
      Using plasma obtained from subjects in the 2 trials, the investigators will conduct an&#xD;
      exploratory mechanistic nested case-control study to address Specific Aim 3. Biomarkers of&#xD;
      selected mechanisms underlying CVC-associated thrombus formation, particularly thrombin&#xD;
      generation, will be compared between subjects with and without CADVT. The investigators will&#xD;
      use Bayesian methods to improve the efficiency in the conduct and analyses of these studies.&#xD;
      The CRETE Studies will provide high-quality age-appropriate evidence that will inform&#xD;
      preventive strategies against CADVT and decrease harm in hospitalized children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">July 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2026</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Older children 1-17 years old and infants &lt;1 year old will be randomized separately. Older children will be randomized 2:1 to prophylactic dose of enoxaparin or control stratified by age. Infants will be randomized 1:1:1 to therapeutic dose of enoxaparin with high or low anti-Xa target or control stratified by age.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The CRETE Studies are open-label with blinded endpoint. Systematic ultrasonographic assessment will be performed with the images blindly and centrally adjudicated.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of children with CADVT</measure>
    <time_frame>Up to removal of CVC (maximum of 28 days)</time_frame>
    <description>Thrombus in the central vein where the CVC was inserted that is diagnosed with systematic ultrasonographic surveillance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of children with any VTE</measure>
    <time_frame>Up to removal of CVC (maximum of 28 days)</time_frame>
    <description>Thrombus in the deep vein of any extremity or PE that is confirmed radiologically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children with clinically apparent CADVT</measure>
    <time_frame>Up to removal of CVC (maximum of 28 days)</time_frame>
    <description>Any CADVT, except one that is only diagnosed with the systematic ultrasonographic surveillance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children with clinically apparent VTE</measure>
    <time_frame>Up to removal of CVC (maximum of 28 days)</time_frame>
    <description>Any VTE, except one that is only diagnosed with the systematic ultrasonographic surveillance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children with clinically relevant bleeding</measure>
    <time_frame>Maximum of 36 hours after the last dose of enoxaparin</time_frame>
    <description>Bleeding that is fatal, with drop in hemoglobin by â‰¥2 g/dl in 24 hours, requires medical or surgical intervention to restore hemostasis, or in the retroperitoneum, pulmonary or central nervous system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children with any bleeding</measure>
    <time_frame>Maximum of 36 hours after the last dose of enoxaparin</time_frame>
    <description>Any overt or macroscopic evidence of bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children with heparin-induced thrombocytopenia</measure>
    <time_frame>Maximum of 36 hours after the last dose of enoxaparin</time_frame>
    <description>Unexplained drop in platelet count to &lt;50 x 10^3/mcL or by 50 percent of baseline platelet count in the ICU within 21 days following exposure to heparin, and with a positive anti-platelet factor 4 antibody.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Enoxaparin (Older Children Prophylactic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prophylactic dose of enoxaparin for older children 1-17 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (Older Children)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care without placebo for older children 1-17 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin (Infants Therapeutic High Anti-Xa Target)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic dose of enoxaparin for infants &lt;1 year old with anti-Xa target of &gt;0.5-1 IU/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin (Infants Therapeutic Low Anti-Xa Target)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic dose of enoxaparin for infants &lt;1 year old with anti-Xa target of 0.2-0.5 IU/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (Infants)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care without placebo for infants &lt;1 year old.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.</description>
    <arm_group_label>Enoxaparin (Infants Therapeutic High Anti-Xa Target)</arm_group_label>
    <arm_group_label>Enoxaparin (Infants Therapeutic Low Anti-Xa Target)</arm_group_label>
    <arm_group_label>Enoxaparin (Older Children Prophylactic)</arm_group_label>
    <other_name>Lovenox</other_name>
    <other_name>Clexane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. &gt;36 weeks corrected gestational to &lt;17 years old&#xD;
&#xD;
          2. &lt;24 hours after insertion of an untunneled CVC&#xD;
&#xD;
          3. CVC inserted in the internal jugular or femoral vein&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Radiologic diagnosis of CADVT in the site of insertion in prior 6 weeks&#xD;
&#xD;
          2. Currently receiving an antithrombotic agent, e.g., LMWH, UFH, warfarin and aspirin,&#xD;
             but not UFH at dose to maintain patency of a vascular catheter&#xD;
&#xD;
          3. Presence of clinically relevant bleeding, i.e., hemoglobin decreased â‰¥2 g/dl in 24&#xD;
             hours, required medical or surgical intervention to restore hemostasis, or in the&#xD;
             retroperitoneum, pulmonary, intracranial or central nervous system, in the prior 60&#xD;
             days&#xD;
&#xD;
          4. Surgery in the prior 7 days&#xD;
&#xD;
          5. Major trauma in the prior 7 days&#xD;
&#xD;
          6. Presence of coagulopathy, i.e., INR &gt;2.0, aPTT &gt;50 seconds or platelet count &lt;50 x&#xD;
             10^3/mcL&#xD;
&#xD;
          7. Presence of renal failure, i.e., creatinine clearance &lt;30 mL/min/1.73 m2&#xD;
&#xD;
          8. Known hypersensitivity to heparin or pork products&#xD;
&#xD;
          9. Laboratory confirmed HIT&#xD;
&#xD;
         10. Current pregnancy or lactation&#xD;
&#xD;
         11. Presence of an epidural catheter&#xD;
&#xD;
         12. Limitation of care&#xD;
&#xD;
         13. Previous enrollment in the CRETE Studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Vincent Faustino, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Pediatrics, Yale School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>E. Vincent Faustino, MD, MHS</last_name>
    <phone>203-785-4651</phone>
    <email>vince.faustino@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tara McPartland, MSW, MPH</last_name>
    <phone>203-737-7173</phone>
    <email>tara.mcpartland@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Kong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Loi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Children's Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>E. Vincent Faustino, MD, MHS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta, Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rajit Basu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stead Family Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christina Cifra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Philip Spinella, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marianne Nellis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jill Cholette, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Fareri Children's Hospital</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthew Pinto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ranjit Chima, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Muszynski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Kavanagh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Athena Zuppa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Oliver Karam, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sheila Hanson, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>child</keyword>
  <keyword>critical illness</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>enoxaparin</keyword>
  <keyword>thrombin generation</keyword>
  <keyword>bleed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

